Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Filip K. Knop Clear advanced filters
  • Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding between one of the most commonly used second-line agents, glimepiride, and the recently approved dipeptidyl peptidase 4 inhibitor linagliptin.

    • Mikkel Christensen
    • Filip K. Knop
    News & Views
    Nature Reviews Endocrinology
    Volume: 8, P: 576-578
  • Here the authors show that the human gut microbiome can recover after a clinically relevant, broad-spectrum antibiotic treatment and characterization of the resistome indicates that antibiotic resistance genes can impact the recovery process.

    • Albert Palleja
    • Kristian H. Mikkelsen
    • Oluf Pedersen
    Research
    Nature Microbiology
    Volume: 3, P: 1255-1265
  • Treatment with liraglutide (3.0 mg once daily for 3 years), a glucagon-like peptide 1 receptor agonist that lowers levels of glucose and reduces body weight, reduced the risk of 'on treatment' type 2 diabetes mellitus (T2DM) versus placebo in patients with prediabetes and obesity. Whether this treatment affects the natural history of the progression from prediabetes to T2DM remains to be established.

    • Tina Vilsbøll
    • Filip K. Knop
    News & Views
    Nature Reviews Endocrinology
    Volume: 13, P: 320-322
  • This Review highlights mechanisms of glucagon secretion from pancreatic α-cells, including paracrine actions in islets and α-cell–β-cell crosstalk. Dysregulated glucagon secretion in metabolic diseases is also considered and the clinical potential of targeting glucagon is discussed.

    • Sofie Hædersdal
    • Andreas Andersen
    • Tina Vilsbøll
    Reviews
    Nature Reviews Endocrinology
    Volume: 19, P: 321-335
  • Characterizing mice lacking Inositol Polyphosphate-4-Phosphatase Type II B (INPP4B), Zhang et al. discovered that SREBP1 signaling is activated in livers of Inpp4b−/− males leading to development of NAFLD and insulin resistance. When fed high fat diet, Inpp4b−/− males develop type II diabetes, inflammation of adipose tissue, and prostate neoplasia. These findings provide insights into INPP4B protective role from metabolic syndrome.

    • Manqi Zhang
    • Yasemin Ceyhan
    • Irina U. Agoulnik
    ResearchOpen Access
    Communications Biology
    Volume: 4, P: 1-15
  • In this Review, the authors describe the physiology of glucagon-like peptide 1 (GLP1) and its role in type 2 diabetes mellitus (T2DM), the currently available and emerging GLP1 receptor agonists and their use to treat T2DM and other indications.

    • Andreas Andersen
    • Asger Lund
    • Tina Vilsbøll
    Reviews
    Nature Reviews Endocrinology
    Volume: 14, P: 390-403